The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The therapeutic monoclonal antibody market
Open accessAbstract
Since the commercialization of the first therapeutic monoclonal antibody product in 1986, this class of biopharmaceutical products has grown significantly so that, as of November 10, 2014, forty-seven monoclonal antibody products have been approved in the US or Europe for the treatment of a variety of diseases, and many of these products have also been approved for other global markets. At the current approval rate of ∼ four new products per year, ∼ 70 monoclonal antibody products will be on the market by 2020, and combined world-wide sales will be nearly $125 billion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Production of recombinant protein therapeutics in cultivated mammalian cells
Wurm, F. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1026 · Cited by 2,032
Research works printed but not linked: 15
- Bioprocess Technology Consultants [Internet], 2014, bioTRAK® database
- Drugs@FDA [Internet], 1939, Food and Drug Administration, Center for Drug Evaluation and Research
- 10.1038/clpt.2009.295 · DOI · Paper page
- 10.1038/nbt1204-1513 · DOI · Paper page
- Greb E, 2012, Pharmaceutical Technol, 36, 46
- 10.1002/btpr.1874 · DOI
- 10.1016/j.tibtech.2010.12.001 · DOI
- Chollangi S, 2014, Bioprocess Int, 12, 48
- 10.12665/J124.Sha · doi:10.12665/j124.sha
- 10.2174/1566524053152898 · doi:10.2174/1566524053152898
- 10.18356/a1b0c169-en · DOI · Paper page
- 10.1002/bit.24602 · DOI
- 10.1002/btpr.1884 · DOI
- 10.1016/j.jbiotec.2014.04.028 · DOI
- 10.1016/j.jbiotec.2013.11.007 · DOI
Cited by
Alternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607
Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics
Bannas, P., Hambach, J., & Koch-Nolte, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01603 · Cited by 572
Edmondson, S. D., Yang, B., & Fallan, C. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.04.030 · Cited by 422
IgG Fc engineering to modulate antibody effector functions
Wang, X., Mathieu, M., & Brezski, R. J. (2018) · Protein & Cell · doi:10.1007/s13238-017-0473-8 · Cited by 356
Therapies for rare diseases: therapeutic modalities, progress and challenges ahead
Tambuyzer, E., Vandendriessche, B., Austin, C. P., Brooks, P. J., Larsson, K., Miller Needleman, K. I., Valentine, J., Davies, K., Groft, S. C., Preti, R., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0049-9 · Cited by 357
Metadata
- Authors
- Ecker, D. M., Jones, S. D., & Levine, H. L.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2015-01-02
- Volume
- 7
- Issue
- 1
- Pages
- 9-14
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W2094052190
- Cited by
- 1,286
- References
- 1
- FWCI
- 76.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The therapeutic monoclonal antibody market. https://app.cochat.ai/papers/10.4161/19420862.2015.989042
- The paper
- Ecker, D. M., Jones, S. D., & Levine, H. L. (2015). The therapeutic monoclonal antibody market. mAbs. https://doi.org/10.4161/19420862.2015.989042
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
